KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1897-4287
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer ; volume:10 ; number:4 ; day:10 ; month:12 ; year:2012 ; pages:1 ; date:12.2012
Hereditary cancer in clinical practice ; 10, Heft 4 (10.12.2012), 1, 12.2012
- Urheber
-
Bar, Julia K.
- Beteiligte Personen und Organisationen
-
Lis-Nawara, Anna
Lebioda, Arleta
Jonkisz, Anna
Jeleń, Michał
Dobosz, Tadeusz
SpringerLink (Online service)
- DOI
-
10.1186/1897-4287-10-S4-A25
- URN
-
urn:nbn:de:1111-2016073118903
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bar, Julia K.
- Lis-Nawara, Anna
- Lebioda, Arleta
- Jonkisz, Anna
- Jeleń, Michał
- Dobosz, Tadeusz
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases
Colorectal cancer with KRAS mutation
Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer
HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment
Is HER2 amplification predictable by digital immunohistochemistry?
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
Detektion von KRAS-Gen-Mutationen beim Bronchialkarzinom
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases
Colorectal cancer with KRAS mutation
Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer
HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment
Is HER2 amplification predictable by digital immunohistochemistry?
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
Detektion von KRAS-Gen-Mutationen beim Bronchialkarzinom
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases
Colorectal cancer with KRAS mutation
Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer
HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment
Is HER2 amplification predictable by digital immunohistochemistry?
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
Detektion von KRAS-Gen-Mutationen beim Bronchialkarzinom
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis